News
XNCR
19.11
-5.68%
-1.15
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
NASDAQ · 20h ago
Analysts Conflicted on These Healthcare Names: Xencor (XNCR) and Pfizer (PFE)
TipRanks · 1d ago
Xencor updates on cash position as of 2024-end
Seeking Alpha · 1d ago
Xencor Highlights Progress in Drug Development Pipeline
TipRanks · 1d ago
Weekly Report: what happened at XNCR last week (0106-0110)?
Weekly Report · 2d ago
Weekly Report: what happened at XNCR last week (1230-0103)?
Weekly Report · 01/06 10:16
Weekly Report: what happened at XNCR last week (1223-1227)?
Weekly Report · 12/30/2024 10:12
Weekly Report: what happened at XNCR last week (1216-1220)?
Weekly Report · 12/23/2024 10:16
XENCOR INC <XNCR.O>: RAYMOND JAMES ADDS STOCK TO ITS ANALYST CURRENT FAVORITES LIST
Reuters · 12/18/2024 13:45
U.S. RESEARCH ROUNDUP-First Solar, GE Vernova, Williams-Sonoma
Reuters · 12/18/2024 06:54
The Math Shows IJR Can Go To $137
NASDAQ · 12/16/2024 12:44
Weekly Report: what happened at XNCR last week (1209-1213)?
Weekly Report · 12/16/2024 10:17
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
NASDAQ · 12/12/2024 17:00
Xencor Price Target Announced at $37.00/Share by Wells Fargo
Dow Jones · 12/12/2024 14:55
Wells Fargo Initiates Coverage On Xencor with Overweight Rating, Announces Price Target of $37
Benzinga · 12/12/2024 14:45
Xencor’s Promising Pipeline and Strategic Partnerships Drive Buy Rating
TipRanks · 12/12/2024 11:35
Xencor initiated with an Overweight at Wells Fargo
TipRanks · 12/12/2024 11:30
Promising Prospects for Xencor’s Plamotamab in Autoimmune Treatments Drive Buy Rating
TipRanks · 12/10/2024 11:46
Weekly Report: what happened at XNCR last week (1202-1206)?
Weekly Report · 12/09/2024 10:16
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
NASDAQ · 12/04/2024 14:55
More
Webull provides a variety of real-time XNCR stock news. You can receive the latest news about Xencor through multiple platforms. This information may help you make smarter investment decisions.
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.